九典制药获得马来酸曲美布汀片药品注册证书

Core Viewpoint - JiuTian Pharmaceutical (300705.SZ) has received the drug registration certificate for Trimebutine Maleate Tablets from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the gastrointestinal treatment market [1] Group 1: Product Information - Trimebutine Maleate Tablets are indicated for the treatment of irritable bowel syndrome and gastrointestinal motility disorders, addressing symptoms such as loss of appetite, nausea, vomiting, belching, bloating, abdominal rumbling, abdominal pain, diarrhea, and constipation [1] - The drug was first approved for market release in France in 1970 and is currently available in various forms including tablets, capsules, and dry mixed suspensions in both domestic and international markets [1]